Hansen Pharmaceuticals (002412) issued an announcement that the company recently obtained the "Drug Registration Certificate" for the chemical drug "Empagliflozin Tablets" approved and issued by the State Drug Administration. The generic name of the drug is empagliflozin tablets, the dosage form is tablets, the specification is 10mg, and the registration classification is chemical drug Class 4. According to the announcement, the drug registration standard number is YBH32972024, and the approval conclusion shows that the drug meets the registration requirements and has been approved.

After obtaining the registration certificate, empagliflozin tablets can be produced and sold domestically, further enriching the company's product line and helping to enhance market competitiveness. However, the announcement also pointed out that the future production and sales of drugs may be affected by factors such as changes in the market environment, so there is uncertainty in the profit level, and investors need to make decisions carefully.

In the first three quarters of 2024, Hanson Pharmaceuticals achieved revenue of 694 million yuan and net profit attributable to shareholders of the parent company of 131 million yuan.

https://finance.eastmoney.com/a/202502113316249265.html